Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Gains from Investment Securities (2021 - 2025)

Mereo BioPharma (MREO) has disclosed Gains from Investment Securities for 4 consecutive years, with -$196000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 432.2% to -$196000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$668000.0, a 186.64% decrease, with the full-year FY2024 number at $1.5 million, up 215.21% from a year prior.
  • Gains from Investment Securities was -$196000.0 for Q3 2025 at Mereo BioPharma, down from $101000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.3 million in Q4 2021 to a low of -$542000.0 in Q1 2023.
  • A 4-year average of $414929.3 and a median of $64000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 182.66% in 2024, then plummeted 432.2% in 2025.
  • Mereo BioPharma's Gains from Investment Securities stood at $5.3 million in 2021, then tumbled by 96.33% to $195000.0 in 2023, then plummeted by 180.51% to -$157000.0 in 2024, then fell by 24.84% to -$196000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Gains from Investment Securities are -$196000.0 (Q3 2025), $101000.0 (Q2 2025), and -$416000.0 (Q1 2025).